Immune restoration disease and changes in CD4+ T-cell count in HIV- infected patients during highly active antiretroviral therapy at Zewditu memorial hospital, Addis Ababa, Ethiopia

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Huruy, Kahsay ^a,b   Kassu, Afework ^a,c   Mulu, Andargachew ^a,b   Wondie, Yemataw ^a,b  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CRYPTOCOCCOSIS; ETHIOPIA; FEMALE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TOXOPLASMOSIS; TUBERCULOSIS;

EID: 78650280821     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-7-46     Document Type: Article

References (31)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860. 10.1056/NEJM199803263381301, 9516219.
2. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, Balakrishnan P. Incidence of Immune Reconstitution Syndrome in HIV/Tuberculosis -Co-infected Patients After Initiation of Generic Antiretroviral Therapy in India. J Acquir Immune Defic Syndr 2004, 37:1574-76. 10.1097/00126334-200412150-00007, 15577411.
3. Shelburne SA, Hamill RJ, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002, 81:213-217. 10.1097/00005792-200205000-00005, 11997718.
4. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003, 5:67-79.
5. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-infected persons after initiation of highly active antiretroviral therapy. Ann.Intern.Med 2000, 133:447-453.
6. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immune- restitution disease involving the acute and adaptive response. Clin. Infect. Dis 2000, 30:882-890. 10.1086/313809, 10880300.
7. Foudraine NA, Hovenkamp E, Notermans DW, Meenhorst PL, Klein MR, Lange JM, Miedema F, Reiss P. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13:177-184. 10.1097/00002030-199902040-00005, 10202823.
8. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the Immune reconstitution inflammatory syndrome in HIV patients in South Africa: Prospective study. AIDS 2008, 22:601-610. 10.1097/QAD.0b013e3282f4a607, 18317001.
9. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006, 42:418-427. 10.1086/499356, 16392092.
10. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005, 19:399-406. 10.1097/01.aids.0000161769.06158.8a, 15750393.
11. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 2007, 11:417-423.
12. Lawn SD, Myer L, Bekker LG, Miller FR. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005, 5:361-373. 10.1016/S1473-3099(05)70140-7, 15919622.
13. Federal HIV/AIDS prevention and control office Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. MOH 2007, Federal HIV/AIDS prevention and control office.
14. Cheesbrough M. District laboratory practice in tropical countries. Part I. 1998, 191-239. Cambridge University Press, Cambridge, England.
15. Klotz SA, Aziz Mohammed A, Girmai Woldemichael M, Worku Mitku M, Handrich M. Immune Reconstitution Inflammatory Syndrome in a Resource-Poor Setting. JIAPAC 2009, 8:122-127.
16. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Inf Dis 2006, 42:1639-46.
17. Shelburne S, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers more questions. J Antimicrob Chemother 2006, 57:167-170. 10.1093/jac/dki444, 16354748.
18. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, Laurence J, Loeff MSV, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523. 10.1016/S1473-3099(08)70184-1, 2804035, 18652998.
19. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O'Shaughnessy M, Montaner J. Non tuberculosis Mycobacterial Immune Reconstitution Syndrome In HIV- Infected Patients: Spectrum of disease and Long - Term Follow Up. Clin Infec Dis 2005, 41:1483-94.
20. Jevtović DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005, 6:140-143.
21. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615-27. 10.1097/01.aids.0000131375.21070.06, 15280772.
22. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. Journal of Infection 2006, 53:357-363. 10.1016/j.jinf.2006.01.002, 16487593.
23. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, Rodgers M, Mclntyre MQ, Abraham LJ, French MA. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043-47. 10.1097/00002030-200210180-00009, 12370503.
24. Woods ML, MacGinley R, Eisen D, Allworth AM. HIV combination therapy: partial immune reconstitution unmasking latent cryptococcal infection. AIDS 1998, 12:1491-94. 10.1097/00002030-199812000-00011, 9727570.
25. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005, 19:1043-49. 10.1097/01.aids.0000174450.70874.30, 15958835.
26. Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM, Eron J, Sanne I, Powderly W, Hogg E, Suckow C, Zolopa A. Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLoS ONE 2010, 5:e11416. 10.1371/journal.pone.0011416, 2895658, 20617176.
27. WHO/UNU/UNICEF Iron deficiency anaemia. Assessment, prevention and control. A guide for programme managers. 2001, Geneva, World Health Organization, (WHO/NHD/01.3), WHO/UNU/UNICEF.
28. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004, 39:1038-46. 10.1086/424009, 15472858.
29. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004, 38:S49-55. 10.1086/381447, 14986275.
30. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2007, 186:23-31.
31. Jiang W, Shao L, Zhang Y, Zhang S, Meng C, Xu Y, Huang L, Wang Y, Wang Y, Weng X, Zhang W. High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-γ release assay among HIV-infected individuals in BCG-vaccinated area. BMC Immunol 2009, 10:31-37. 10.1186/1471-2172-10-31, 2700818, 19476627.